A prospective before‐and‐after trial of a medical emergency team

“It often has been said that it is not work but worry that kills.” This statement, from an early 20thcentury JAMA editorial entitled Physicians and longevity, argued that hard work and a resolute focus on unravelling the unknown in medicine were rewarded with living to an advanced age. Paragons of this phenomenon included Virchow, the famed pathologist (nearly 81 years), Harvey, discoverer of the circulation (79 years), and the French surgeon Ambroise Paré, who, “in spite of a life of trials and years of unhealthy camp life, lived to be nearly 75”.

[1]  M. Whitehead,et al.  The concepts and principles of equity and health. , 1992, International journal of health services : planning, administration, evaluation.

[2]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[3]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[4]  Peter Jüni,et al.  Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? , 2002, BMJ : British Medical Journal.

[5]  G. Moore,et al.  Effects of a medical emergency team on reduction of incidence of and mortality from unexpected cardiac arrests in hospital: preliminary study , 2002, BMJ : British Medical Journal.

[6]  J. Byles,et al.  Using socioeconomic evidence in clinical practice guidelines , 2003, BMJ : British Medical Journal.

[7]  Rinaldo Bellomo,et al.  The Medical Journal of Australia ISSN: , 2000 .

[8]  G. Naglie,et al.  The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[9]  J. Avorn,et al.  The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. , 2003, The Journal of rheumatology.

[10]  A. Seaton.  “There's none so blind as the double blind.” Discuss , 2003, BMJ : British Medical Journal.

[11]  K. McGeechan,et al.  Lessons from early large‐scale adoption of celecoxib and rofecoxib by Australian general practitioners , 2003, The Medical journal of Australia.

[12]  S. Gabriel,et al.  The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  T. MacDonald,et al.  Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs , 2003, Gut.

[14]  B. Spiegel,et al.  The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis , 2003, Annals of Internal Medicine.

[15]  A. Rodger.  What drives the NHS? , 2004, The Medical journal of Australia.

[16]  E. Harris,et al.  Achieving equity in the Australian healthcare system , 2004, The Medical journal of Australia.